-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

Benzinga·09/16/2026 17:20:00
Listen to the news
BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.